此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

RTX001肝硬化自体工程巨噬细胞 (EMERALD)

2026年10月2日 更新者:Resolution Therapeutics Limited

一项开放标签期1/2多中心研究,以评估RTX001自体巨噬细胞在患有肝功能不全(Emerald)的肝肝硬化参与者中的安全性,耐受性和功效

The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.

研究概览

详细说明

EMERALD is a first-in-human Phase 1/2 open label study designed to evaluate the safety, tolerability and efficacy of RTX001 in patients with end-stage liver disease following recent hepatic decompensation.

RTX001 is an autologous engineered macrophage cell therapy. It is made from a person's own cells. It uses a type of white blood cell called macrophages. These cells have been found to help improve liver function in participants with liver cirrhosis.

To produce RTX001, each study participant must first undergo steps that will allow us to collect white blood cells using a process called leukapheresis. Leukapheresis is a procedure in which white blood cells are separated from the collected blood using a specific machine. The collected white blood cells are sent to a manufacturing facility to make RTX001. As RTX001 is an autologous product, this means that it can only be given back to the same participant who donated the cells. The term "autologous macrophage" used in the study title refers to white blood cells (macrophages) coming from the same person's body (autologous).

The data in this study will be compared to the external control data from a Natural History Study called OPAL (NCT06380335) which is being conducted in a similar participant population from primarily the same study sites in the United Kingdom (UK) and EU.

研究类型

介入性

注册 (估计的)

30

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Bristol、英国、BS2 8HW
        • Bristol Royal Infirmary
      • Edinburgh、英国、EH16 4SA
        • Royal Infirmary of Edinburgh
      • Glasgow、英国、G4 0SF
        • Glasgow Royal Infirmary
      • Liverpool、英国、L7 8YE
        • Royal Liverpool University Hospital
      • London、英国、SE5 9RS
        • King's College Hospital
      • London、英国、SW17 0QT
        • St George's Hospital
      • London、英国、W2 1NY
        • St Mary's Hospital
      • Nottingham、英国、NG5 1PB
        • Nottingham University Hospital
      • Barcelona、西班牙、08035
        • Hospital Universitari Vall d'Hebron
      • Córdoba、西班牙、14004
        • Hospital Universitario Reina Sofía
      • Madrid、西班牙、28046
        • Hospital Universitario La Paz
      • Madrid、西班牙、28007
        • Hospital General Universitario Gregorio Marañon
      • Madrid、西班牙、28034
        • Hospital Universitario Ramón y Cajal
      • Seville、西班牙、41013
        • Hospital Universitario Virgen del Rocío
      • Valencia、西班牙
        • Hospital Le Fe

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Individuals eligible to participate in this study must meet the following criteria:

Inclusion Criteria:

  1. Male or female age ≥18-75 years.

  2. Patient confirms willingness/ability to comply with all study procedures.

  3. Diagnosis of liver cirrhosis based on at least one of:

    1. Clinical and radiological features that correlate with a diagnosis of cirrhosis.
    2. Transient elastography (Fibroscan) >15 kPa.
    3. Previous liver biopsy confirming histological features of cirrhosis.
  4. Aetiology of liver disease of steatotic liver disease including MASLD or Met-ALD or ALD

    a. Participants with alcohol-related liver disease (ALD or Met-ALD) only if they are confirmed to not be drinking alcohol above Met-ALD limits defined in this protocol. (N.B. No more than 34% of the total treated participants in this protocol will be ALD [excludes Met-ALD]).

  5. Hospitalised as an inpatient for a recent major hepatic decompensation event including ascites, hepatic encephalopathy, variceal bleed, HRS-AKI or SBP, this being the only hospitalisation for an hepatic decompensation event hospitalisation within the last 6 months, and where recent is defined as within 6 weeks of hospital discharge.

  6. Outpatient: Medically refractory ascites (ONLY), that recurs (i.e., second therapeutic LVP) within a 6-month period. Medically refractory ascites is defined by the repeated (≥2) need for LVP (i.e., therapeutic, not diagnostic) at least once per 8 weeks despite best medical attempts to control the ascites by sodium restriction and diuretic treatment, as confirmed by the Investigator. Onset is defined as the date of the second therapeutic LVP.

  7. Confirmatory PEth alcohol test <200 ng/ml

  8. MELD score of 12-20 taken within two weeks of 'qualifying' decompensation event.

  9. No known contradictions to filgrastim or leukapheresis procedure.

  10. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

  11. Willing and able to give signed informed consent, and if applicable assent.

Participants are excluded from the study if any of the following criteria apply:

Exclusion Criteria:

  1. Liver cirrhosis due to:

    1. any viral hepatitidies, or
    2. autoimmune and cholestatic aetiologies including, but not limited to, primary biliary cholangitis and primary sclerosing cholangitis.
  2. Acute liver disease in the absence of underlying liver cirrhosis, including, but not limited to, drug induced liver injury.

  3. Any current organ failure requiring more than outpatient supportive care, and not associated with the participant's qualifying hepatic decompensation event.

  4. Known splenomegaly ≥16 cm.

  5. Thrombocytopenia <50×109/L.

  6. Presence or suspicion of any of the following co-morbidities:

    1. History of liver transplantation or other organ transplant.
    2. ACLF.
    3. Sepsis (with positive microbial cultures) or as defined by the Principal Investigator, unless stable and is at least 4 weeks after having completed a full course of IV antibiotics.
    4. Known human immunodeficiency virus.
    5. Known syphilis.
    6. Known human T-lymphotropic virus 1.
    7. Pulmonary embolism.
    8. Hepatocellular carcinoma, or any active malignant disease within the last five years, (excluding non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, benign polyps etc.).
    9. Co-hepatic morbidities e.g., portal vein thrombosis.
    10. Participants with hepatic hydrothorax are excluded unless it is a small hydrothorax, not clinically apparent, that is detected incidentally by radiologic evaluation that does not require clinical intervention.
    11. Chronic renal impairment (on dialysis) or unresolved AKI.
    12. Acute or chronic heart failure (New York Heart Association Grade III/IV).
    13. Porto-pulmonary hypertension.
    14. Severe chronic lung disease e.g., chronic obstructive pulmonary disease or interstitial lung disease where the forced expiratory volume in the first second (FEV1) is less than 50% and/or FEV1/forced vital capacity is less than 60%.
    15. Hepatopulmonary syndrome.
    16. Previous or current treatment with multiple infusions of albumin for therapeutic intent. [Use of albumin infusion at the time of large volume paracentesis for circulatory support is allowed.]
    17. Significant untreated/unstable psychiatric disease.
    18. Transjugular intrahepatic portosystemic shunt (TIPSS).
  7. As judged by the Investigator, any evidence of intercurrent illness that is either life threatening or of clinical significance such that it might limit compliance with study procedures.

  8. Current or planned use of immunomodulators or immunosuppressive medication; note: low doses of corticosteroids up to 10 mg/kg/day prednisone or equivalent are permitted, or inhaled steroids to manage asthma.

  9. Received a gene or cell therapy at any time.

  10. Current or planned use of a live attenuated vaccines four weeks or fewer prior to enrolment (and for 3 months after the last administered dose of RTX001).

  11. Received any investigational product within the past 6 months, or five half-lives (whichever is longer) or participated in another investigational interventional study within 30 days prior to the screening visit.

  12. Participants with a known hypersensitivity to dimethyl sulfoxide (DMSO).

  13. Judgment by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.

  14. For female participants only - pregnant or breast-feeding or plans to become pregnant over the next year, or of childbearing potential and unwilling to comply with contraceptive requirements.

  15. Alcohol misuse in the period between identification of the participant as potentially suitable for this study to Screening (Visit 1), defined as alcohol intake greater than three units/day for females and four units/day for males, or binge drinking (>14 units/day) as determined by the Investigator. N.B. One unit is equivalent to 14 g of alcohol: a half-pint (~240 mL) of beer, one glass (125 mL) of wine or one (25 mL) measure of spirits.

  16. Intake of non-medically supervised drugs of abuse that are judged (by the Investigator) to be a high risk to the participants acute health or which makes the participant likely to be non-compliant with follow-up.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:RTX001

Following the manufacture of RTX001, participants will be assigned into one of two groups based on the compensation status of their cirrhosis at this time as follows:

  • Stabilised Group: Participants who remain clinically stable, as assessed by the Investigator, since their qualifying decompensation event.
  • Subsequent Decompensation Group: Participants who have had a further decompensation event following their leukapheresis and/or the RTX001 manufacturing process.

Treatment will be identical for both groups, and each participant will receive a maximum of four doses of RTX001 by intravenous infusion Patients in the Subsequent Decompensation Group need to have stabilised before receiving treatment.

RTX001 is an autologous engineered regenerative macrophage cell therapy

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety and Tolerability
大体时间:2.5 years

Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

2.5 years
Safety and Tolerability
大体时间:At each infusion; day of infusion up to two weeks post-infusion

Incidence and severity of infusion reactions

At each infusion; day of infusion up to two weeks post-infusion

次要结果测量

结果测量
措施说明
大体时间
Time to clinical event
大体时间:2.5 years

Time to clinical event, defined as all hepatic decompensation events including SBP and/or HRS-AKI, new listing for liver transplantation, liver transplantation, or death.

2.5 years
Time to mortality
大体时间:2.5 years

Time-to all-cause mortality (hepatic related and all-cause).

2.5 years
Change in Model for End Stage Liver Disease score 3.0 (MELD3.0)
大体时间:2.5 years

To evaluate changes in Model for End Stage Liver Disease (MELD3.0) scores, from baseline to end of study in the Stabilised Group participants.

2.5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年10月15日

初级完成 (估计的)

2028年8月29日

研究完成 (估计的)

2028年11月29日

研究注册日期

首次提交

2024年11月6日

首先提交符合 QC 标准的

2025年2月6日

首次发布 (实际的)

2025年2月12日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年10月2日

最后验证

2026年10月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅